Corvus Pharmaceuticals (CRVS) Short-term Investments (2024 - 2026)

Corvus Pharmaceuticals' Short-term Investments history runs 3 years deep, the most recent figure standing at $196.6 million for Q1 2026.

• On a quarterly basis, Short-term Investments changed N/A year-over-year to $196.6 million in Q1 2026; TTM through Mar 2026 was $196.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $52.2 million, up 20.71% from the prior year.
• Short-term Investments advanced to $196.6 million in Q1 2026 per CRVS's latest filing, from $52.2 million in the prior quarter.
• Across five years, Short-term Investments topped out at $196.6 million in Q1 2026 and bottomed at $43.2 million in Q4 2024.
• The 3-year median for Short-term Investments is $52.2 million (2025), against an average of $97.3 million.
• Biggest YoY gain for Short-term Investments was 20.71% in 2025; the steepest drop was 20.71% in 2025.
• Year by year, Short-term Investments stood at $43.2 million in 2024, then increased by 20.71% to $52.2 million in 2025, then soared by 276.84% to $196.6 million in 2026.
• Per Business Quant, the three latest CRVS Short-term Investments figures stand at $196.6 million (Q1 2026), $52.2 million (Q4 2025), and $43.2 million (Q4 2024).